Intervention strategies for seasonal and emerging respiratory viruses with drugs and vaccines targeting viral surface glycoproteins

Ralph A. Tripp; John Stambas

doi:10.3390/v13040625

Intervention strategies for seasonal and emerging respiratory viruses with drugs and vaccines targeting viral surface glycoproteins

Ralph A. Tripp
, John Stambas

Research output: Contribution to journal › Review article › peer-review

6 Citations (Scopus)

61 Downloads (Pure)

Abstract

Vaccines and therapeutics targeting viral surface glycoproteins are a major component of disease prevention for respiratory viral diseases. Over the years, vaccines have proven to be the most successful intervention for preventing disease. Technological advances in vaccine platforms that focus on viral surface glycoproteins have provided solutions for current and emerging pathogens like SARS-CoV-2, and our understanding of the structural basis for antibody neutralization is guiding the selection of other vaccine targets for respiratory viruses like RSV. This review discusses the role of viral surface glycoproteins in disease intervention approaches.

Original language	English
Article number	625
Pages (from-to)	1-8
Number of pages	8
Journal	Viruses
Volume	13
Issue number	4
DOIs	https://doi.org/10.3390/v13040625
Publication status	Published - Apr 2021
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.3390/v13040625Licence: CC BY

ArticleFinal published version, 237 KBLicence: CC BY

Cite this

@article{7395386cb71d41178852b3827a39fec3,

title = "Intervention strategies for seasonal and emerging respiratory viruses with drugs and vaccines targeting viral surface glycoproteins",

abstract = "Vaccines and therapeutics targeting viral surface glycoproteins are a major component of disease prevention for respiratory viral diseases. Over the years, vaccines have proven to be the most successful intervention for preventing disease. Technological advances in vaccine platforms that focus on viral surface glycoproteins have provided solutions for current and emerging pathogens like SARS-CoV-2, and our understanding of the structural basis for antibody neutralization is guiding the selection of other vaccine targets for respiratory viruses like RSV. This review discusses the role of viral surface glycoproteins in disease intervention approaches.",

keywords = "Respiratory syncytial virus, Respiratory virus, RSV, SARS-CoV-2, Therapeutics, Vaccines",

author = "Tripp, \{Ralph A.\} and John Stambas",

note = "Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2021",

month = apr,

doi = "10.3390/v13040625",

language = "English",

volume = "13",

pages = "1--8",

journal = "Viruses",

issn = "1999-4915",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "4",

}

TY - JOUR

T1 - Intervention strategies for seasonal and emerging respiratory viruses with drugs and vaccines targeting viral surface glycoproteins

AU - Tripp, Ralph A.

AU - Stambas, John

PY - 2021/4

Y1 - 2021/4

N2 - Vaccines and therapeutics targeting viral surface glycoproteins are a major component of disease prevention for respiratory viral diseases. Over the years, vaccines have proven to be the most successful intervention for preventing disease. Technological advances in vaccine platforms that focus on viral surface glycoproteins have provided solutions for current and emerging pathogens like SARS-CoV-2, and our understanding of the structural basis for antibody neutralization is guiding the selection of other vaccine targets for respiratory viruses like RSV. This review discusses the role of viral surface glycoproteins in disease intervention approaches.

AB - Vaccines and therapeutics targeting viral surface glycoproteins are a major component of disease prevention for respiratory viral diseases. Over the years, vaccines have proven to be the most successful intervention for preventing disease. Technological advances in vaccine platforms that focus on viral surface glycoproteins have provided solutions for current and emerging pathogens like SARS-CoV-2, and our understanding of the structural basis for antibody neutralization is guiding the selection of other vaccine targets for respiratory viruses like RSV. This review discusses the role of viral surface glycoproteins in disease intervention approaches.

KW - Respiratory syncytial virus

KW - Respiratory virus

KW - RSV

KW - SARS-CoV-2

KW - Therapeutics

KW - Vaccines

UR - https://www.scopus.com/pages/publications/85105127624

U2 - 10.3390/v13040625

DO - 10.3390/v13040625

M3 - Review article

C2 - 33917411

AN - SCOPUS:85105127624

SN - 1999-4915

VL - 13

SP - 1

EP - 8

JO - Viruses

JF - Viruses

IS - 4

M1 - 625

ER -

Intervention strategies for seasonal and emerging respiratory viruses with drugs and vaccines targeting viral surface glycoproteins

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this